Panel plans to regulate patented drug prices

Tags: News

Rates of cancer, HIV, hepatitis drugs to drop if plan implemented; move may provoke ire of Big Pharma

A government panel has proposed that prices of patented medicines be based on the country’s per capita income, a move that would substantially reduce prices of costly drugs made by global pharma firms.

The proposal, which seeks the input of other government agencies as well as industry groups, could provoke the ire of Big Pharma, which has clashed with India over protection of intellectual property, price regulations for generic drugs, and compulsory licences for costly medicines.

A panel formed under the ministry of chemicals and fertilisers has recommended setting up a committee to negotiate with drugmakers to fix prices of costly drugs used to treat deadly diseases such as cancer, HIV and hepatitis.

The proposal is the latest in a series of measures taken by India to make medicines more affordable for the country’s 1.2 billion population. “If we compare the per-capita income with the prices of patented medicines in countries like Australia or France, prices in India are comparatively high and hence, they need to be regulated,” a senior ministry official told Reuters, declining to be identified because he was not authorised to speak with media.

Generic medicines account for more than 90 per cent of India’s $13 billion pharmaceuticals market. US-based Abbott Laboratories has the largest share of the overall Indian drug market followed by Cipla.

The proposal, posted late on Monday on the ministry website, cites as an example the lung-cancer drug erlotinib HCL, sold by Roche Holding as Tarceva. In India, it costs Rs 35,450 for one month of 100 mg tablets, equivalent to Rs 1,21,085 in France and Rs 121,650 in Australia. Based on per-capita gross national incomes, if the drug costs Rs 35,450 in India, its respective cost would be just Rs 11,643 in France and Rs 10,309 in Australia based on per capita income in the respective countries, the report said.

The Organization of Pharmaceutical Producers of India, which represents foreign drugmakers in India, did not reply to questions from Reuters.

“If stringent price regulations are enforced then latest drugs will not be made available in India,” said Ameet Hariani, managing partner at Hariani.


  • Modi must clearly say that preservation of cows is not about manslaughter

    Instead of in-fighting between hindus and muslims, India should fight poverty and maintain its values of diversity and tolerance, as advised by Presid


Stay informed on our latest news!


Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs


Urs Schoettli

America lacks will to contain China

Recently both the Chinese leader Xi Jinping and Indian prime ...

Zehra Naqvi

Exercise gets creative juices flowing

Ever known that feeling of being sluggish and drowsy, of ...

Bubbles Sabharwal

You are what you believe yourself to be

The Gita says a man is what his shraddha is. ...


William D. Green

Chairman & CEO, Accenture